ELV Unusual Options Activity — 2026-03-27

🛡️ ELV $2.6M Covered Call - Big Money Locking In Gains on a Beaten-Down Health Insurer!

📅 March 27, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just sold $2.6 MILLION worth of ELV June $280 calls - collecting premium on 948 contracts with the stock sitting at $284.89, barely above the strike. This is the classic move of an institutional investor who owns the stock and is capping their upside to generate income while Elevance Health fights its way through CMS sanctions, Medicaid margin pressure, and a looming Q1 earnings report in April. With Vol/OI at 25x and only 64 contracts in existing open interest, this is a brand new position - not a roll or a hedge on an existing trade.

---

📊 Company Overview

Elevance Health (ELV) is one of America's largest managed care companies, navigating a rough stretch in 2026:

• 🏥 What they do: Manages health insurance plans including Medicaid, Medicare Advantage, and commercial (Blue Cross Blue Shield) for 45+ million members across 14 states
• 💰 Market Cap: $64.9B
• 🏢 Sector: Managed Care (Health Insurance)
• 📈 Exchange: NYSE
• 📊 Current Price: $284.89
• ⚠️ Key Story: Stock has dropped ~37% from its 2024 all-time high of $544 as CMS sanctions freeze Medicare Advantage enrollment and Medicaid margins hit their projected trough

---

💰 The Option Flow Breakdown

📊 The Tape

🤓 What This Actually Means

Let me break this down in plain English:

• 💸 $2.6 million collected: 948 contracts at $27.00 each ($27.00 x 100 shares x 948 = ~$2.56M) in premium income
• 📍 Strike $280 is slightly ITM - the stock is at $284.89, meaning the strike is just 1.7% below current price
• ⏰ June 18, 2026 expiration - that's the June quarterly options expiration, 83 days out
• 📊 Vol/OI ratio = 25x - volume is 25 times the existing open interest of 64 contracts; the z-score here is an extreme 202.51 - this trade stands out as happening fewer than a handful of times a year at this size relative to historical activity on this strike
• 🤝 MID fill + SELL = Sell-to-Open (STO) - executed at the midpoint, someone is writing (selling) these calls, not buying them
• 🎯 Breakeven for the seller: $307.00 ($280 strike + $27.00 premium received) - the stock has to close above $307 at expiration for this seller to lose money

What's the thesis here?

Real talk: this is almost certainly a covered call on a large stock position. The trader owns ELV shares and is selling the right to have them called away at $280 in exchange for $27/share cash today. That $27 represents 9.5% of the current stock price collected as income over just 83 days - an annualized yield of about 42%.

Why would someone cap their upside at $280 when the stock is already at $284.89? Because they're not convinced ELV breaks meaningfully higher before June. With Q1 earnings landing in ~25 days and CMS sanctions still unresolved, this looks like a "take the income, protect the position" move rather than a bullish swing trade.

Why is this unusual? The Vol/OI of 25x and z-score of 202.51 confirm this isn't routine premium selling activity. The June $280 strike had essentially no open interest (just 64 contracts) before this trade. Someone sized up specifically here - at an ITM strike that maximizes collected premium while still leaving some upside buffer ($280 vs. $284.89 spot).

---

📈 Technical Setup / Chart Check-Up

YTD Performance

ELV has been in full damage-control mode in 2026. The stock started the year near $345 and has shed roughly 17% YTD to trade around $284-285. The catalyst timeline is brutal to look at:

• 📉 January selloff: Q4 2025 earnings beat but 2026 guidance came in way below expectations ($25.50 adjusted EPS vs. consensus ~$27.21) - stock sold off sharply from $345
• 📉 March collapse: CMS sanctions announced March 2 froze new Medicare Advantage enrollment; stock dropped 8%+ in a single session
• 📊 Current level: $284-285 - sitting just above the 52-week low of $273.71
• 🎢 Volatility: At 37% annualized implied vol, this is trading more like a mid-cap biotech than a healthcare blue chip right now

Key takeaway: ELV is bouncing along the bottom after a brutal few months. The question is whether the April earnings report re-sets the narrative or drives another leg down.

Gamma-Based Support & Resistance Analysis

Current Price: ~$284

The gamma exposure map shows where options dealers have built concentrated positions, creating natural price magnets and barriers:

🔵 Support Levels (Put Gamma Below Price):

• $280 - The single most important support level with 1.21B total gamma exposure - this is also the strike on today's covered call, which is no coincidence. Market makers holding heavy put gamma here will actively defend this level
• $270 - Secondary support at 0.26B gamma
• $260 - Extended support at 0.17B gamma
• $250 - Deep floor at 0.08B gamma

🟠 Resistance Levels (Call Gamma Above Price):

• $290 - First resistance at 0.31B gamma (just 2% above - tight overhead cap)
• $300 - Major resistance at 1.25B gamma (the biggest call gamma wall on the board - this is the line in the sand for bulls)
• $310 - Extended resistance at 0.31B gamma
• $320 - Further out at 0.27B gamma
• $340 - Longer-term resistance at 0.39B gamma

What this means for traders: The $280 gamma support and the $300 gamma wall create a narrow 7% trading range as the dominant near-term battleground. The dealer positioning essentially pins ELV in the $280-$300 zone until a major catalyst shifts the picture. The covered call at $280 is basically betting this stock doesn't rip cleanly through $300 before June 18 - and right now, gamma structure agrees.

Net GEX Bias: Bullish - overall call gamma slightly exceeds put gamma, suggesting dealers lean bullish, which provides a mild tailwind for the stock.

Implied Move Analysis

Options market expected ranges by expiration:

• 📅 April 17 OPEX (21 days): ±$20.23 (±7.1%) → Range: $264 - $305
• 📅 May 15 OPEX: Upper $310, Lower $259
• 📅 June 19 Triple Witch (THE TRADE expiration zone): Upper $315, Lower $254
• 📅 Yearly LEAP (March 2027): ±$72.80 (±25.6%) → Range: $212 - $357

Translation: The options market expects ELV could swing anywhere from $254 to $315 by the June quarterly expiration - roughly when this covered call expires. The seller collected $27 in premium and the stock is at $284.89, meaning they break even on the short call at $307 - which sits inside the June implied upper range of $315. That means the market gives maybe a 30-35% probability the stock closes above $307 by June 18. The seller keeps the full $27 if ELV closes anywhere below $280 at expiration.

---

🎪 Catalysts

🔥 Upcoming Catalysts

Q1 2026 Earnings - Expected April 21-22, 2026 📊

This is the most critical near-term event - just 25 days away. The market is watching:

• 🩺 Medical Loss Ratio trajectory (2026 target: 90.2% - Q4 2025 came in at a worrying 93.5%)
• 🏛️ CMS sanctions remediation update - any progress toward getting Medicare Advantage enrollment unfrozen?
• 💊 Medicaid margin commentary - management called 2026 the projected trough at -1.75% margin
• 📈 Carelon growth - the $71.7B revenue segment growing 33% YoY is the one bright spot
• 💬 Consensus Q1 EPS estimate is ~$10.40, revised down from $11.38 in February - bar is low

CMS Sanctions Resolution - Timeline Unknown, Potentially Q2-Q3 2026 🏛️

The enrollment freeze on Medicare Advantage plans goes into effect March 31 - literally this Monday. Until Elevance demonstrates it's fixing its 7-year-old data submission failure, new MA enrollment stays frozen. If this drags past October, it poisons the 2027 Annual Enrollment Period - a potentially catastrophic outcome.

CMS 2027 MA Rate Proposal - Final Rates Published by Early April 2026 📋

CMS proposed 2027 MA rates with virtually zero increase. The final rates land in early April. Another near-zero outcome would further compress MA margins in 2027.

Carelon Leadership Transition - May 4, 2026 🔄

President Peter Haytaian departs May 4; CFO Mark Kaye picks up Carelon oversight in addition to finance duties. Markets will assess whether dual-hatting the CFO on the highest-growth segment is smart consolidation or stretched leadership.

2027 MA Star Ratings - Published October 2026 ⭐

Elevance improved to 55% of members in 4+ star plans (up from 40%) - a key quality bonus driver. The October 2026 release will confirm whether that trajectory continues.

✅ Recent Catalysts (Already Happened)

CMS Medicare Advantage Sanctions - March 2, 2026 🚨

CMS hit Elevance with intermediate sanctions for failing to submit risk adjustment data through electronic systems over seven years, instead using flash drives despite repeated warnings. Enrollment freeze effective March 31. Stock dropped 8%+ the day of the announcement, 1.9 million existing MA members are not affected but new enrollment stops cold.

Q4 2025 Earnings - January 28, 2026 📊

Q4 revenue of $49.3B (+10% YoY) missed consensus slightly, but adjusted EPS of $3.33 beat the $3.10 estimate. The 2026 guidance of at least $25.50 adjusted EPS (a 16% decline from $30.29 in 2025) is what rattled the market. MLR of 93.5% showed medical costs are running hot.

Management Restructuring - February 26, 2026 🔄

Elevance announced C-suite consolidation alongside reaffirmed FY2026 guidance. Markets initially interpreted the restructuring neutrally, though leadership risk on Carelon drew some analyst scrutiny.

Deutsche Bank Downgrade - January 2026 📉

Deutsche Bank cut ELV to Hold from Buy with a $320 target, citing regulatory uncertainty and rising utilization - an analyst flag that preceded the CMS sanctions headlines by weeks.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, analyst targets, and the catalyst calendar, here are the scenarios through the June 18, 2026 covered call expiration:

📈 Bull Case (25% probability)

Target: $300-$315

How we get there:

• ✅ Q1 earnings beat expectations - MLR improves meaningfully from Q4's 93.5%
• 🏛️ CMS signals a clear path to lifting sanctions quickly
• 📊 2027 MA final rates land better than the "near zero" proposal
• 💊 Medicaid margin trough commentary confirms improvement trajectory heading into 2027
• 🚀 Stock breaks through the $290 gamma wall, then squeezes toward the $300 resistance

Covered call outcome at $307+: Stock gets called away at $280, leaving the writer with $280 + $27 premium = $307/share. If the stock is at $315, the seller has given up $8/share of upside - that's the cost of writing this covered call.

Uncovered stock position P&L at $315: Up 10.6% from $284.89. A solid gain but the covered call caps it.

🎯 Base Case (50% probability)

Target: $270-$295 range

Most likely scenario:

• 📊 Q1 earnings roughly in line - MLR improves modestly but CMS sanctions create noise
• ⚖️ No quick resolution on MA enrollment freeze - situation grinds into summer
• 🔄 Stock oscillates in the $275-$295 range, pinned by gamma at $280 support and $300 resistance
• 📈 Some recovery from recent oversold levels but no decisive breakout

Covered call outcome: Stock stays below $280 at expiration. Seller keeps the full $27/share ($2.56M total) and retains the stock position. This is the win condition for today's trade.

📉 Bear Case (25% probability)

Target: $254-$270

What could go wrong:

• 😰 Q1 MLR comes in worse than expected - confirms medical costs are structural, not cyclical
• 🚨 CMS escalates sanctions or adds new penalties
• 📉 2027 MA final rates confirm near-zero increase, forcing additional guidance cuts
• 💸 Broader managed care sector selloff (UNH or HUM guidance miss drags the group)
• 📊 Break below $280 gamma support triggers move toward $270, then $260

Covered call outcome: Stock drops below $280. Seller keeps the $27 premium, providing partial protection. A move to $260 means the stock position is down $24.89/share ($284.89 - $260), but the $27 premium collected offsets that entire loss, keeping the position roughly breakeven.

This is actually the key insight on this trade: the $27 premium creates a $27 downside cushion. The effective cost basis on the stock drops from $284.89 to $257.89 for this seller.

---

💡 Trading Ideas

🛡️ Conservative: "Collect Rent" - Covered Call Mimic

Play: Own 100 shares of ELV, sell 1x June 2026 $280 call

Structure: Covered call on existing or new ELV position

Why this works:

• 💰 Collect ~$27/share in premium income immediately (9.5% yield in 83 days)
• 🛡️ The premium provides downside cushion down to an effective $257.89 cost basis
• 📊 The $280-$300 gamma range creates a natural profit zone where the stock stays below the strike and you pocket the full premium
• 📅 April earnings (April 21-22) lands well before expiration - you get the event catalyst within the trade window
• 🎯 Even if the stock gets called away at $280, you've locked in $307 effective sale price ($280 + $27)

Risk: Stock drops sharply below $257.89 (below current implied downside range of ~$254) and the premium doesn't fully cover the loss. This is a stock-replacement risk, not an options-specific risk.

Position sizing: This is the institutional play - match your stock position size. Retail: consider 200-500 shares with 2-5 covered call contracts.

Risk level: LOW-MODERATE (defined income, capped upside) | Skill level: Beginner-Intermediate

⚖️ Balanced: "Wait for the Dip" - Cash-Secured Put

Play: Sell 1x ELV June 2026 $270 put, collect ~$12-14/share in premium

Why this works:

• 🎯 Get paid to agree to buy ELV at $270 - that's below the 52-week low of $273.71
• 💰 ~$12-14 collected provides an effective purchase price of $256-258
• 📊 The $270 gamma support is meaningful - dealers have positions to defend there
• ⏰ Same June expiration - captures Q1 earnings and early CMS resolution timeline
• ⚖️ If the stock stays above $270 you keep the full premium without ever touching the stock

Risk: Stock blows through $270 on a catastrophic catalyst (sanctions escalation, earnings disaster) and you're buying at an effective $257-258 during a freefall. Only do this if you'd actually want to own ELV at $270.

Position sizing: 1 contract requires $27,000 in cash set aside as collateral. 5 contracts = $135,000 allocated. Premium collected: $6,000-7,000.

Risk level: MODERATE (defined risk at contract level, but substantial if stock collapses) | Skill level: Intermediate

🚀 Aggressive: "Bounce Trade" - Debit Call Spread

Play: Buy ELV May $285 call, sell ELV May $300 call (debit spread, ~$5-7 cost)

Why this works (and why it's risky):

• 🎯 Bets on a bounce into Q1 earnings - if stock rips back toward $300, this spread pays out
• 💸 Defined risk: you can only lose the $5-7 debit paid (vs. buying outright calls)
• 📈 Max profit: ~$8-10 per spread if ELV is above $300 at May expiration
• ⏰ Short window forces a decisive move - no time for a slow grind
• 📊 The $300 call gamma wall is a natural target for the short leg

Why it could blow up:

• 😰 Q1 earnings disappoint and the stock drops to $270 - spread expires worthless
• ⏰ 50 days to May expiration means time decay eats at value if stock doesn't move
• 🚨 CMS sanctions headlines could crush the stock at any moment before earnings

Position sizing: Risk ONLY what you can afford to lose completely. 10 spreads at $6 = $6,000 risk for ~$9,000 max profit.

Risk level: HIGH (100% loss of debit if stock stays flat or drops) | Skill level: Intermediate-Advanced

---

⚠️ Risk Factors

The landmines between here and June 18:

• 🏛️ CMS Sanctions Duration is the #1 Unknown: If the MA enrollment freeze isn't lifted before October 2026, it poisons the Annual Enrollment Period - the primary MA membership window. Per Healthcare Dive's reporting, there's no clear resolution timeline. This goes from annoying to catastrophic if it drags into the fall.

• 📉 Q1 MLR Print Could Break the Stock: Q4's 93.5% MLR was the alarming number. Management's full-year target is 90.2%. That's a massive improvement needed starting with Q1. If April 21-22 shows MLR staying elevated, the market will question whether $25.50 EPS guidance is achievable at all.

• 💸 "One Big Beautiful Bill Act" Structural Damage: The federal Medicaid legislation mandates work requirements and eligibility checks that CBO estimates will reduce Medicaid coverage by 10.5M+ people by 2034. Elevance's Medicaid book across 24 states is structurally exposed.

• 📊 Analyst Estimate Revisions Still Negative: Zacks cut Q1 EPS from $11.38 to $10.40 and Q2 from $8.51 to $6.30 in February. Downward revisions create earnings risk in both directions - beats relative to low expectations, or misses that confirm the downward trend.

• 🔄 Carelon Leadership Risk: CFO Mark Kaye now runs both finance and the $71.7B Carelon services business. Carelon is the one segment growing 33% YoY - it's the company's growth engine, and now it's being dual-hatted. Execution stumbles here hit the bullish recovery thesis directly.

• 🏥 Peer Contagion Risk: UnitedHealth (UNH) and Humana (HUM) are facing the same Medicaid and MA headwinds. A sector-wide negative pre-announcement would drag ELV regardless of company-specific execution.

• ⚔️ For the Covered Call Seller Specifically: If somehow ELV gets a blockbuster catalyst (quick CMS resolution + earnings beat + rate surprise) and rips to $320+, the seller of today's $280 covered call has left a lot of money on the table. That's the tradeoff - income now vs. missing a potential recovery rally.

---

🎯 The Bottom Line

Here's the deal: A large institutional player just collected $2.6 million in premium by writing covered calls on ELV at the $280 strike - slightly below where the stock is trading today. They're saying: "I own this stock, I'm not sure it rips higher in the next 83 days given everything on the plate, so let me get paid $27/share to cap my upside and cushion my downside."

What this trade tells us:

• 🎯 The seller does NOT expect a near-term breakout above $307 (the call breakeven)
• 💰 They want income now - $2.6M collected today versus hoping for a rally that may not materialize before June
• ⏰ The June 18 expiration is deliberate - it captures Q1 earnings (April 21-22) and gives a look at early CMS sanctions resolution progress without committing to the full-year thesis
• 📊 The vol/OI of 25x and z-score of 202.51 says this is abnormal sized for this strike - someone is making a real statement about their expectations for the next 83 days

The covered call story in three scenarios:

• ✅ Stock below $280 at June 18: Seller pockets the full $27/share ($2.56M), still owns the stock. Best outcome - keep all the premium, keep the shares.
• ⚖️ Stock between $280-$307 at June 18: Stock gets called away at $280, effective sale price is $307 (strike + premium). Profitable, just misses some upside.
• ❌ Stock above $307 at June 18: Stock still called away at $280 effective price. Seller leaves money on the table - every dollar above $307 is foregone profit.

If you're bullish on ELV:

• 📊 The $280 gamma support and $300 gamma wall define the near-term range - watch for a break above $300 as the signal that the recovery narrative is taking hold
• ⏰ Mark April 21-22 on your calendar - Q1 earnings is the first real checkpoint for the thesis that 2026 is the trough year
• 💡 A confirmed path to CMS sanctions resolution would be the single most bullish catalyst available - watch for any 8-K filings from Elevance on this topic

If you're watching from the sidelines:

• 🎯 TD Cowen named ELV their "Best Idea for 2026" with a $400 target; the median analyst target across 21 analysts is $398 - implying ~40% upside from here if the recovery plays out
• 📊 The stock trades at only 12.68x forward P/E vs. the 15.54x industry average and UNH's 18.69x - the discount is real
• ⏰ Wait for Q1 confirmation that MLR is improving before committing capital - that's the proof point that 2026 is actually the trough

If you're cautious:

• ⚠️ A break below $280 (the strongest gamma support level on the board) would be technically significant and could trigger a move toward $270, then $260
• 🛡️ The covered call strategy the whale just employed is the smart way to stay long while protecting yourself - collect the premium, reduce your cost basis, and let the catalysts play out
• 😰 The $254 implied lower range for June is not far from the 52-week low of $273.71 - a bad Q1 print could test both simultaneously

Key dates to mark:

• 📅 March 31, 2026 - CMS MA enrollment freeze officially takes effect - watch for any last-minute Elevance filing
• 📅 Early April 2026 - CMS 2027 MA final rate publication - critical for margin outlook
• 📅 April 21-22, 2026 (estimated) - Q1 2026 earnings - THE make-or-break moment for the recovery thesis
• 📅 May 4, 2026 - Carelon President Haytaian officially departs; CFO Kaye assumes dual role
• 📅 June 18, 2026 - THIS COVERED CALL EXPIRES - moment of truth for the $2.6M premium trade

Final verdict: ELV is deeply unloved right now - down 37% from its all-time high with regulatory headaches, earnings pressure, and Medicaid reform hanging over every quarter. But that's exactly the environment where covered call strategies make sense: you stay long for the eventual recovery while getting paid handsomely to wait it out. Today's $2.6M covered call bet is institutional money playing it smart - collecting nearly 10% of the stock's value as income in a quarter packed with binary catalysts. Watch the April earnings print above everything else. If MLR starts trending back toward management's 90.2% target, the recovery narrative gets traction. If it doesn't, those $27 in collected premium are going to earn their keep.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance does not guarantee future results. Covered calls cap upside potential and do not eliminate downside risk in the underlying stock. Cash-secured puts require significant capital and can result in substantial losses if the stock declines significantly. Always do your own research and consider consulting a licensed financial advisor before trading.

---

About Elevance Health: Elevance Health is the second-largest U.S. health insurer, operating managed care plans including Medicaid, Medicare Advantage, and commercial insurance under the Blue Cross Blue Shield brand across 14 states. The company serves 45+ million members and generated $197.6B in operating revenue in 2025, with a market cap of $64.9B listed on the NYSE.